Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Flow Cytometry 3Methylprednisolone 2Immunologic Techniques 2Alemtuzumab 2sargramostim 1saracatinib 1resiquimod 1poly ICLC 1pembrolizumab 1liposomal doxorubicin 1dexamethasone acetate 1dexamethasone 21-phosphate 1cediranib 1aldesleukin 1Therapeutics 1Tacrolimus 1Psychiatric Rehabilitation 1Prednisone 1Moxifloxacin 1Microarray Analysis 1Interleukin-12 Subunit p35 1Interferon-alpha 1Immunoenzyme Techniques 1Granisetron 1Gene Expression Profiling 1ER 30346 1Dexamethasone 1Deferasirox 1Data Collection 1Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × resiquimod × Gynecologic × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡